Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(MLO-0651) UVB Phototherapy in the Treatment of Psoriasis Vulgaris


 Return to List of Clinical Studies
 Return to List of Protocols for Psoriasis and Skin Diseases
Mechanism of Action of Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris

Principal Investigator:


Investigators:

Contact Information:
Patricia Gilleaudeau
Rockefeller University
1230 York Avenue
New York, NY 10065
Telephone: 1-800-RUCARES
Alt. Telephone: 212-327-8333
Contact Information:
Mary Sullivan-Whalen
Telephone: 212-327-7212
Alt. Telephone:
E-Mail:


Enrollment Status:
Closed to Enrollment

Brief Summary of Protocol:
Psoriasis is a chronic, debilitating skin disease affecting millions of Americans, and is considered one of the most prevalent immune-mediated inflammatory diseases.

In this study, patients will be treated with an appropriate dose of NB-UVB three times a week for up to 12 weeks, and serial biopsies will be taken for genomic analysis and characterization of leukocytes infiltrating the tissue. Peripheral blood will be collected at the start and end of the study, and an optional shave biopsy may be collected at the start of the study. This study could lead to new understandings of the mechanism of action of NB-UVB in normal skin of psoriasis patients (non-lesional skin) and psoriatic lesional skin, new disease applications for NB-UVB, and even new therapeutic targets.



Detailed Description of Protocol:
Patients will receive a program of regular, monitored NB-UVB treatment.

Patients will be treated 3 times per week, and a full course of therapy is 12 weeks. Profile:
20 patients (Fitzpatrick skin phototypes I-VI) of either sex will be sequentially enrolled.



What specifically makes a person eligible for the study?
You may be eligible to enter this study:

You may be eligible if you:
• have a history of chronic plaque psoriasis vulgaris, for at least six months
• have ≥10% body surface affected
• are age 18 or greater


Gender:
Both

Age(s):
18+

Children permitted to participate:
No

Potential Benefits.....
As NB-UVB therapy has been used for many years, the benefits of this therapy for psoriasis to each individual volunteer are well-documented. We hope to gain a greater understanding of the underlying mechanism of this effective therapy with this study, which may benefit others with this disorder and, potentially, those with other inflammatory dermatoses. The relative risks of this treatment are well established.



Compensation:
Compensation will not be offered to participants. Patients are offered free therapy with an effective treatment modality.